Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (10,5 Mio. €): Biomarker bei atopischer Dermatitis und Psoriasis Hor 01.04.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Text

Biomarker bei atopischer Dermatitis und Psoriasis

Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes.


Geförderte Unternehmen:

Firmenname Förderungssumme
Academisch Ziekenhuis Leiden 410.938 €
AIT Austrian Institute OF Technology GmbH 466.711 €
Almirall SA 0,00 €
Boehringer Ingelheim Internationalgesellschaft mbH 0,00 €
Centre Hospitalier Universitaire Vaudois 81.250 €
Christian-Albrechts-Universitaet ZU Kiel 1.478.387 €
Den Selvejende Institution Dansk Borneastma Center 544.119 €
Eurice European Research AND Project Office GmbH 666.685 €
Hahn-Schickard-Gesellschaft FUR Angewandte Forschung e. V. 149.625 €
Heinrich-Heine-Universitaet Duesseldorf 221.625 €
Information Technology FOR Translational Medicine (Ittm) SA 460.360 €
ITA-Suomen Yliopisto 175.125 €
Karolinska Institutet 599.033 €
King's College London 1.573.555 €
Klinikum DER Technischen Universität München (TUM Klinikum) 28.530 €
Kobenhavns Universitet 274.500 €
Leo Pharma AS 0,00 €
London School of Hygiene and Tropical Medicine Royal Charter 182.957 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Deutschland GmbH 0,00 €
Stichting Amsterdam UMC 161.875 €
Stichting Radboud Universitair Medisch Centrum 258.500 €
Stichting Radboud Universiteit 0,00 €
Tampereen Korkeakoulusaatio sr 415.801 €
Tartu Ulikool 193.500 €
Technische Universitaet Muenchen 185.000 €
The Provost, Fellows Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin 0,00 €
The University of Edinburgh 103.380 €
UCB Biopharma 0,00 €
Universitaetsklinikum Freiburg 347.720 €
Universitaetsklinikum Hamburg-Eppendorf 63.125 €
Universitat Wien 208.350 €
Universite Du Luxembourg 488.936 €
University of Bristol 746.636 €
University of Dundee 13.777,61 €

Quelle: https://cordis.europa.eu/project/id/821511

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.